BRIEF-Legend Biotech Announces Promising Preliminary Clinical Data For LB2501

Legend Biotech

Legend Biotech

LEGN

0.00

June 2 (Reuters) - Legend Biotech Corp LEGN.O:

  • LEGEND BIOTECH: PROMISING INITIAL PHASE 1 CLINICAL DATA FOR LB2501 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

  • LEGEND BIOTECH: 100% ORR (6/6) OBSERVED IN DOSE LEVEL 2 COHORT, INCLUDING CR RATE OF 83.3% (5/6) IN PATIENTS WITH RELAPSED/ REFRACTORY NHL

  • LEGEND BIOTECH: DATA DEMONSTRATES ROBUST IN VIVO CAR-T EXPANSION WITHOUT LYMPHODEPLETING CHEMOTHERAPY OR BRIDGING THERAPY

  • LEGEND BIOTECH: NO DOSE-LIMITING TOXICITIES, SERIOUS ADVERSE EVENTS, OR NEUROTOXICITY REPORTED


Further company coverage: LEGN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.